---
title: Better Respiratory Triage | Improve Care Decisions | MediPines
description: Enhance COPD and outpatient respiratory healthcare with the AGM100, enabling rapid respiratory triage and informed care decisions without lab reliance, improving patient outcomes and reducing costs.
---
[Skip to main content](https://medipines.com/site-of-care#main-content)
[ ](https://medipines.com?hsLang=en)
- [AGM100](https://medipines.com/medipines-agm100-overview)
- [Uses](https://medipines.com/providers)
- [Clinical Evidence](https://medipines.com/clinical-research)
- [Show submenu for Company Company](https://medipines.com/about)
- [About](https://medipines.com/about)
- [News](https://medipines.com/respiratory-medicine-updates)
- [Support](https://medipines.com/customersupport)
Open main navigation
Close main navigation
- [AGM100](https://medipines.com/medipines-agm100-overview)
- [Uses](https://medipines.com/providers)
- [Clinical Evidence](https://medipines.com/clinical-research)
- Show submenu for Company Company
- Company
- [Company](https://medipines.com/about)
- [About](https://medipines.com/about)
- [News](https://medipines.com/respiratory-medicine-updates)
- [Support](https://medipines.com/customersupport)
- [Contact Us](https://medipines.com/contact)
[Contact Us](https://medipines.com/contact?hsLang=en)
# Health Transformation Requires Better Respiratory Triage and Care Decisions
MediPines aligns with provider priorities by enabling rapid, point-of-care respiratory triage and immediate care decisions, allowing primary care, emergency and rural sites to act without relying on delayed or inaccessible hospital-based or specialist diagnostics such as ABGs and PFTs/spirometry.
Designed for real-world settings where pulmonary diagnostics and cardiorespiratory baselining are unavailable, leading to unnecessary delays and sub-optimal care at the site of service.
0.94
AUROC — best in
published literature
\<1 min
Non-invasive
point-of-care result
94%
Specificity for
respiratory failure risk
Relevant for health system leaders overseeing rural health, population health, and care delivery strategy.
## High impact care decisions
Every outpatient encounter contains a judgment call: escalate the patient, or manage locally? Without an objective respiratory signal, that decision rests on incomplete proxies, SpO2, clinical impression, vitals, that routinely miss early deterioration.
The consequences compound in remote settings: a wrong call in either direction means an avoidable transfer, an unnecessary admission, or a patient discharged too soon. The AGM100 resolves this with a direct measurement of gas exchange, the actual physiological mechanism behind respiratory failure, not a surrogate for it.
Economic Impact
Respiratory conditions are among the highest-cost categories in healthcare, with 30-day readmission rates near 17% and average readmission costs of $16,400 for respiratory system diseases (AHRQ, 2023). The incremental cost of a readmission, relative to the initial admission, is approximately $3,700. Earlier, more accurate triage at the point of care can meaningfully reduce avoidable escalation and downstream cost.
Hospitals using the AGM100 in primary care and emergency departments create a rare dynamic in healthcare: **better care, lower cost, and no added financial burden to adopt and deploy.**
SITE-of-care decisions
## How decisions change at the point of care
In about one minute, the AGM100 gives clinicians the gas exchange data they need to make the three most consequential decisions in respiratory care confidently, at the point of care, without a blood draw or specialist referral.
Escalation decisions
Objective respiratory failure risk stratification at the point of care so the decision to escalate/manage locally is grounded in physiology, not guesswork.
Safely manage locally
Based on gas exchange severity, provide appropriate medications and treatment on-site without scheduling unnecessary specialist visits. High patient safety, lower cost, and fewer avoidable transfers.
Condition monitoring
Repeatable, objective measurements allow care teams to track respiratory status over time supporting chronic disease management and treatment response assessment.
Outpatient respiratory care
## Assess treat and confirm at the site of care
Patients with an SpO2 over 90% who complain of shortness of breath look stable on a pulse oximeter, but hospitals typically admit most of them. An AGM100 assessment shows who can safely go home, who can be treated on site, and who needs to be admitted.
*Below is an illustrative estimate for the new CPT code 0893T and APC 5734. Actual payment varies by payer, applicable coverage and billing rules, and supporting documentation, including time and resources involved.*
Presenting
100
Patients visiting with a respiratory condition. SpO2 over 90%, complaining of shortness of breath. Each receives an AGM100 assessment.
↓
Safe to discharge
40
The assessment shows these patients can safely go home, avoiding an admission they would typically receive.
Treated at site of care
50
Treated with oxygen or COPD drug therapy, then reassessed with AGM100 to see whether they responded.
↓
Responders
30
Responded to treatment and were sent home.
Non-responders
20
Do not respond to treatment and are admitted for further workup
Admitted
10
Require inpatient admission because of severe presentation or sudden decompensation.
**70**sent home the same day after AGM100 assessments and treatment, avoiding unnecessary admissions.
**30**admitted, with no change to current reimbursement
> "We're measuring patients in the ER as a form of triage to determine what kind of care we're going to provide. So far it's been extremely successful. We're intervening much quicker to find out what's going on and then treating them."
Head of Respiratory Therapy · Milwaukee Area Hospital
Chronic disease & care gaps
## Turning routine visits into early detection
For regions that carry higher rates of COPD, heart failure, and pulmonary disease, many patients go undiagnosed until an acute event forces the issue. A brief AGM100 assessment at any visit surfaces gas exchange impairment that standard vitals miss entirely.
Download [Equipping Rural America with 21st Century COPD care.](https://medipines.com/hubfs/Equipping%20Rural%20America%20with%2021st%20Century%20COPD%20care.pdf?hsLang=en)
cLOSE THE Care gap
Routine screening identifies undiagnosed cardiorespiratory conditions before they become hospitalizations.
Applicable at primary care, long-term care, and community health settings.
Longitudinal tracking
Serial measurements build objective respiratory profiles supporting COPD management, CHF monitoring, and treatment response over time.
Built for distributed care
## Portable, low-bandwidth, no lab required.
The AGM100 was designed for care environments where lab infrastructure is limited, specialists are hours away, or care teams are spread across geographies. It requires no network connection to operate, no blood draw, and no specialist to interpret the result.
Critical Access Hospitals
Replace lab-dependent triage with an on-site respiratory assessment that immediately informs admit, transfer, or discharge.
Primary care clinics
A 2-minute test any clinician can perform. Determine appropriate treatment and assess effectiveness.
Long-term care
Monitor residents with chronic respiratory conditions without transport to a facility reducing unnecessary transfers.
Emergency departments
Improve throughput by reducing unnecessary tests. Objective triage of respiratory complaints to narrow differential.
> "With AGM100 alone, I can manage her. I'm not depending on my clinical impression, I'm depending on objective science. I have tests to guide my clinical suspicion."
Ascension Affiliated Pulmonologist
Clinical Evidence
## 15 Years of Science. One Breakthrough.
AGM100's Oxygen Deficit metric has been validated in NIH-funded research against the best predictive tools for respiratory failure in the published literature and outperforms them all.
This level of performance enables real-time triage decisions without reliance on delayed or invasive testing.
“Oxygen Deficit has high prognostic value with a fidelity that exceeds or matches the accuracy of the best predictive tools for respiratory failure in the published literature.”
— Authors who conducted acute patient study using AGM100 | NIH-Funded Study (2025) Conclusion
| Year | Tool | Method | AUROC | Sens. | Spec. | Workflow Implication |
| --- | --- | --- | --- | --- | --- | --- |
| 2010 | LIPS | Risk factor scoring | 0.82–0.84 | 69% | 78% | Limited to ALI/ARDS; requires multiple risk factor assessment |
| 2016 | ROX Index | SpO₂ + RR + FiO₂ | 0.74–0.76 | — | — | Requires high-flow O₂ patients; serial assessments at 2h, 6h, 12h |
| 2021 | Deep Learning | AI algorithms | 0.88–0.90 | — | — | Complex AI infrastructure; substantial data dependency; ongoing |
| 2025 | **AGM100** | Oxygen Deficit (non-invasive) | 0.94 | 81% | 94% | Stand-alone, non-invasive. Point of care. Valid for all cardiorespiratory dyspnea. ~1–2 min. |
★ Highest reported prognostic performance for any noninvasive respiratory metric
Source: NIH-funded study | J. Clin. Med. 2025, 14, 5880
## Reimbursement
The AGM100 is supported by a dedicated AMA CPT® code covering non-invasive cardiorespiratory assessment, with reimbursement pathways through Medicare, Medicaid, and commercial payers.
AMA CPT® code
Dedicated code covering: cardiorespiratory status baseline · non-invasive blood oxygenation · gas exchange impairment assessment.
Eliminates the reimbursement uncertainty that often blocks adoption of new diagnostic tools.
OPPS APC 5734
Hospital outpatient reimbursement mapped and active, supporting use in emergency and outpatient settings.
Training time
Operators are proficient in under one hour. Any qualified facility staff can perform and interpret the assessment with no specialist background required.
## Exploring respiratory care strategy
We'd welcome a brief conversation or are happy to connect with the appropriate member of your team overseeing population health, ACO initiatives, or program deployment.
[Contact us to learn more](https://medipines.com/contact?hsLang=en)
[.png?width=200&height=59&name=MP%20Logo_All-in-One_070820%20(1).png)](https://medipines.com?hsLang=en)
- [Home](https://medipines.com)
- [AGM 100](https://medipines.com/medipines-agm100-overview)
- [About](https://medipines.com/about)
- [Training](https://portal.medipines.com)
©2026 MediPines Corporation. All rights reserved. [Privacy Policy](https://medipines.com/privacy-policy?hsLang=en)
[llms.txt](https://medipines.com/hubfs/llms/llms.txt?hsLang=en)
-
-